NeuroOne Medical Technologies Corporation has significantly expanded its intellectual property portfolio with recent patent approvals from both the United States and European patent offices. The medical technology company, focused on improving surgical care for neurological disorders, received three key patent decisions that strengthen its position in developing advanced electrode technologies.
On September 29, 2025, the United States Patent and Trademark Office issued a Notice of Allowance for U.S. Patent Application 17/860,232, titled "Probe Devices with Temperature Sensors and Related Systems and Methods." This patent covers novel electrode devices incorporating temperature sensors, a critical safety feature for brain ablation procedures. A Notice of Allowance indicates the USPTO has completed examination and determined a patent should be granted, with NeuroOne anticipating formal issuance in the coming months.
The European Patent Office granted European Patent 4013481 on October 1, 2025, covering "Spinal Cord Stimulation Systems, Methods, and Devices." This patent protects novel spinal cord stimulation devices featuring deployable electrode array bodies. The European approval represents NeuroOne's first granted patent in Europe and addresses percutaneous placement technology that could eliminate the need for surgical incisions in treating lower back pain.
Completing the recent approvals, the USPTO issued U.S. Patent 12,435,407 on October 7, 2025, titled "Methods for Making Probe Devices and Related Devices." This patent covers manufacturing methods for neural probe and spinal cord stimulation devices, including specific techniques for arranging probe components and depositing electrode contact material.
These new additions complement NeuroOne's existing portfolio, which includes four additional issued U.S. patents, seven pending U.S. applications, and eight pending foreign applications. The portfolio encompasses various thin-film electrode technologies designed with unique structures to optimize functionality while minimizing device profiles.
Dave Rosa, NeuroOne's chief executive officer, emphasized the strategic importance of these developments. "NeuroOne has made tremendous progress expanding our robust patent portfolio. Our goal is to continue to grow our technology platform to broader use cases and applications," Rosa stated. He specifically highlighted the temperature control feature as "an integral feature of our OneRF Ablation System that provides a critical safety measure for brain ablations for patients suffering from seizures."
The expanded patent protection could have significant implications for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, and chronic pain. By securing intellectual property rights across multiple jurisdictions, NeuroOne strengthens its competitive position in developing minimally invasive solutions that may improve patient outcomes while potentially reducing procedural costs. The company's technology platform addresses neurological disorders through EEG recording, monitoring, ablation, drug delivery, and stimulation solutions. For more information about the company's developments, visit https://nmtc1.com.
The strengthened patent portfolio comes as medical technology companies increasingly compete to develop advanced neurological treatment options. NeuroOne's focus on thin-film electrode technology with temperature sensing capabilities and minimally invasive deployment methods represents important advancements in a field where safety and precision are paramount. These patent approvals provide legal protection for innovations that could meaningfully impact how neurological conditions are treated globally.
